

CURRICULUM VITAE

EMANUELA ROTONDO

PERSONAL INFORMATION

Address

Email

Telefon number

Nationality

Birthday

Psychologist / Psicoterapist/ Neuropsychologist: Number 03/13995 (Psychology and
Psicoterapist board - Lombardia).

ACTUAL OCCUPATION

Aug 2008 – ongoing

- Clinical Neuropsychologist at
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
U.O.S.D. Malattie Neurodegenerative
Via Francesco Sforza, 35 – 20122 Milano (MI) - Italia
- Study coordinator and rater in several clinical pharmaceutical trials (neurodegenerative
disease: Alzheimer Disease, Mild Cognitive Impairment, Multiple Sclerosis) according to
Good Clinical Practice.

EDUCATION

- School in psychotherapy (Cognitive-Behavioural Therapy) Nov 2012 – Nov 2015
A.S.I.P.S.E. 'Scuola di formazione in psicoterapia comportamentale e cognitiva di Milano'
- PhD at Università degli Studi di Milano Apr 2009 – May 2012
'XXIV Ciclo della Scuola di Dottorato in
Scienze fisiopatologiche, neuropsicobiologiche e assistenziali del ciclo della vita'.

- Doctor in Psychology 2003 - 2008
Università degli Studi di Padova
Thesis: *'Analisi dell'eloquio spontaneo in soggetti con Demenza di Alzheimer'*
110Lode/110;
- Secondary School Diploma 1998 - 2003
Liceo Scientifico Giulietta Banzi Bazoli, Lecce 90/100.

WORK EXPERIENCES

- Psychologist in Neuropsychiatric center 2012 - 2015
Fondazione IRRCS Cà Granda Ospedale Maggiore Policlinico
ADHD center
Via Fanti, 9 Milano
- Clinical Neuropsychologist Sep 2007 – Feb 2008
Clinica figlie di San Camillo, Cremona
Neuropsychological assessment and rehabilitation of AD subjects;
- Previous Experience in Clinical Trials:
- GlaxoSmithKline Research and Development Ltd: A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy;
- Sanofi: A phase 2a study to evaluate the effect of rilapladib (SB-659032) on biomarkers related to the pathogenesis and progression of Alzheimer's disease;
- Teva: A 12 months prospective, observational study evaluating impact of DMT treatment on the emotional burden in recently diagnosed multiple sclerosis patients;
- Servier: Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer's Disease;
- Novartis: a 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer's Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody response following repeated I.M. injection of adjuvanted CAD106;

- Novartis: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 1,25mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis;
- Novartis: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 1,25mg FTY720 administered orally once daily versus placebo in patients with relapsing remitting multiple sclerosis;
- Lundbeck: Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil;
- Envivo: A 26-week extension in study of the safety and clinical effects of EVP-6124 in subjects with Alzheimer's Disease currently or previously receiving an Acetylcholinesterase inhibitor medication;
- Merck: A randomized, Placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 with a long term double-blind extension in subject with mild to moderate Alzheimer's Disease (protocol number MK-8931-017);
- Merck: A phase III, randomized, Placebo controlled, parallel-group, double blind clinical trial to study efficacy and safety of MK-8931 in subject with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease - prodromal AD(protocol number MK-8931-019);
- Eli-Lilly: Effect of passive immunization on then progression of mild Alzheimer's disease Solanezumab (LY2062430) versus Placebo (protocol number H8A-MC-LZAX);
- Lilly/Astra Zeneca: A 24-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, safety, tolerability, biomarker, and pharmacokinetic study of AZD3293 in early Alzheimer's disease (AMARANTH study);
- EISAI: A placebo-controlled, double-blind, parallel-group, bayesian adaptive randomization design and dose regimen-finding study to evaluate safety, tolerability and efficacy of BAN2401 in subjects with early Alzheimer's disease;
- TEVA: A multinational multicenter, randomized, parallel group, open-label study to assess medication satisfaction in patients with relapsing remitting multiple sclerosis (RRMS) treated with subcutaneous injection of Copaxone (Glatiramer Acetate 40 mg/ml three times a week compared to 20 mg/mL daily).

SPOKEN LANGUAGES

- English (writing, reading and listening, speaking).

– ABSTRACTS AND PUBLICATIONS

Pietroboni AM, Fumagalli GG, Ghezzi L, Fenoglio C, Cortini F, Serpente M, Cantoni C, Rotondo E, Corti P, Carecchio M, Bassi M, Bresolin N, Galbiati D, Galimberti D, Scarpini E. Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a Large Italian Kindred. Journal of Alzheimer's Disease 2011; 24(2): 253-9
Rotondo M, Galimberti D, Vimercati R, Corti P, Bergamaschini I, Fenoglio C, Serpente M, Cantoni C, De Riz M, Bresolin N, Vergani C, Scarpini E. Cognitive testing and correlation with cerebrospinal fluid A β , τ and P τ levels in subject with mild cognitive impairment. Clinical Neuropathology 29(3): 200-1 (2010). XLVI Annual Meeting of the Italian Association of Neuropathology (AINP) – XXXVI Meeting of the Italian Association for Research on Brain Aging (AIRIC), May 23-25, 2010, Squillace (Catanzaro), Italy
Rotondo E, Galimberti D, Vimercati R, Corti P, Bergamaschini L, Fenoglio C, Serpente M, Cantoni C, De Riz M, Bresolin N, Vergani C, Scarpini E. Cognitive testing and correlation with cerebrospinal fluid Abeta and Ptau levels in subjects with mild cognitive impairment. Journal of Neurology 257, Suppl. 1: S166 (2010). XX Meeting of the European Neurological Society, June 19-23, 2010, Berlin, Germany.
Rotondo E, Galimberti D, Vimercati R, Corti P, Bergamaschini L, Fenoglio C, Serpente M, Cantoni C, De Riz M, Bresolin N, Vergani C, Scarpini E. Cognitive testing and correlation with CSF Abeta, tau and Ptau levels in subjects with Mild Cognitive Impairment. European Journal of Neurology 2010; 17 Suppl. 3: 78. 14th Congress of the European Federation of Neurological Societies, September 25-28, 2010, Geneva, Switzerland.
Pietroboni A, Fumagalli G, Ghezzi L, Fenoglio C, Cortini F, Serpente M, Cantoni C, Rotondo E, Corti P, Bresolin N, Galimberti D, Scarpini E. GRN Asp22fs mutation is associated with highly variable age at onset, clinical phenotype and brain atrophy. Neurological Sciences 31, Suppl.: S323, 2010. XLI Congress of the Italian Neurological Society, October 23-27, 2010, Catania, Italy.
Pietroboni AM, Fumagalli GG, Ghezzi L, Fenoglio C, Cortini F, Serpente M, Cantoni C, Rotondo E, Corti P, Carecchio M, Bassi M, Bresolin S, Galbiati D, Galimberti D, Scarpini E. Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred. Journal of Alzheimer's disease 23, Suppl. 1: S70, 2011. VI SINDem meeting, March 17-19, Milan, Italy.
Pietroboni A, Fumagalli G, Ghezzi L, Fenoglio C, Cortini F, Serpente M, Cantoni C, Rotondo E, Corti P, Bresolin N, Galimberti D, Scarpini E. Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred. Clinical Neuropathology 30(3): 138-9 (2011). XLVII Annual Meeting of the Italian Association of Neuropathology (AINP) – XXXVII Meeting of the Italian Association for Research on Brain Aging (AIRIC), May 19-21, 2011, Genova, Italy.
Fumagalli G, Pietroboni A, Ghezzi L, Fenoglio C, Cortini F, Serpente M, Cantoni C, Rotondo E, Corti P, Carecchio M, Bassi M, Bresolin N, Galbiati D, Galimberti D, Scarpini E. Phenotypic heterogeneity of the progranulin gene Asp22fs mutation in a large Italian kindred. Journal of Neurology 258, Suppl. 1: S185-6 (2011). XXI Meeting of the European Neurological Society, May 28-31, 2011, Lisbon, Portugal.
Corti P, Rotondo E, Vimercati R, Jacini F, Fumagalli GG, Arighi A, Ghezzi L, Bresolin N, Galimberti D, Scarpini E. Cognitive predictors and correlations with biomarkers and functional imaging in patients with Primary Progressive Aphasia. Journal of Alzheimer's disease 29, Suppl. 1: 57, 2012. VII SINDem meeting, March 22-24, Naples, Italy.
Mercurio M, Rotondo E, Corti P, Vimercati R, Jacini F, Fumagalli GG, Arighi A, Ghezzi L, Bresolin N, Galimberti D, Scarpini E. Validation of the Italian Addenbrooke's cognitive examination revise (ACE-R) as a screening test. Journal of Alzheimer's disease 29, Suppl. 1: 75-6, 2012. VII SINDem meeting, March 22-24, Naples, Italy.
Rotondo E, Galimberti D, Vimercati R, Corti P, Marcurio M, Fenoglio C, Serpente M, Ridolfi E, Bresolin N, Scarpini E. Cognitive testing in subjects with MCI: prediction of conversion to AD and correlation with cerebrospinal fluid biomarker levels. Journal of Alzheimer's disease 29, Suppl. 1: 87, 2012. VII SINDem meeting, March 22-24, Naples, Italy.
Arighi A, Donelli C, Galimberti D, Pietroboni AM, De Riz M, Ghezzi L, Fumagalli G, Jacini F, Calvi A, Zago S, Rotondo E, Corti P, Mercurio M, Vimercati R, Fenoglio C, Ridolfi E, Scarpini E. cerebrospinal fluid and neuroimaging biomarkers in posterior cortical atrophy. Journal of Neurology 260, Suppl. 1: S166-7 (2013). XXIII Meeting of the European Neurological Society, June 8-11, 2013, Barcelona, Spain.

Arighi A, Galimberti D, Pietroboni A, De Riz M, Fumagalli G, Ghezzi L, Donelli C, Calvi A, Callea A, Zago S, Rotondo E, Corti P, Mercurio M, Vimercati R, Fenoglio C, Ridolfi E, Rango M, Scarpini E. Cerebrospinal fluid neuroimaging biomarkers in posterior cortical atrophy. <i>Neurological Sciences</i> 34, Suppl.: S247-8, 2013. XLIV Congress of the Italian Neurological Society, November 2-5, 2013, Milan, Italy
Serpente M, Fenoglio C, Clerici F, Bonsi R, Arosio B, Cioffi SM, Rotondo E, Franceschi M, Boneschi FM, Mari D, Mariani C, <u>Scarpini E</u>, Galimberti D. Transmembrane Protein 106B Gene (TMEM106B) Variability and Influence on Progranulin Plasma Levels in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> 2015; 43(3):757-61.
Galimberti D.m, Bonsi R., Fenoglio C., Serpente M., Cioffi S.M.G., Fumagalli G., Arighi A., Ghezzi L., Arcaro M., Mei M., Rotondo E., Scarpini E., Inflammatory molecules in Frontotemporal Dementia: Cerebrospinal fluid signature of progranulin mutation carriers. <i>Brain, Behaviour and Immunity</i> 49 (2015), 182-187.
Abbate C., Trimarchi PD, Rotondo E, Inglese S, Nicolini P, Rossi PD, Arosio B. Spontaneous confabulations in amnesic-mild cognitive impairment due to Alzheimer's disease: a new (yet old) atypical variant?. <i>Neurocase</i>, 2016; 22: 1-10.

I authorize treatment of personal data (D. Lgs 196 del 30/06/03) and I authorize publication on web site of Fondazione IRCCS Cà Granda Ospedale maggiore Policlinico, Milano (art. 15 del D. Lgs. n. 33 14/03/2013). This CV is a self-certification (D.P.R 445/2000).

Milano, 02/12/2016

